Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
Multiple studies find drug to be first diabetes medication to show significant reduction of liver fat.
Read More »Empagliflozin as First Line in Patients with Type 2 and Fatty Liver Disease
SGLT-2 Side Effects
Which is not a side effect of SGLT-2 Inhibitors?
A. Kidney failure
B. Hyperkalemia
C. Ketoacidosis
D. Hypertension
E. Increased cholesterol levels
F. Serious urinary tract infections
G. Increased bladder cancer risk
H. Serious allergic reactions
Follow the link for the answer.
Read More »Update: SGLT2 Inhibitors Linked to Outbreaks of Rare Fournier’s Gangrene
FDA issues new warning regarding SGLT2 inhibitors after 12 cases of rare necrotizing fasciitis emerge.
Read More »SGLT2 Inhibitors: A New Class of Diabetes Medications
What is a SGLT2 Inhibitor? Sodium-glucose co-transporter 2 (SGLT2) inhibitors, also called gliflozin drugs, are a new class of diabetic medications indicated for the treatment of type 2 diabetes. They have also been found to show cardiac benefits in patients with diabetes, and are being studied for possible use in type 1 diabetes. They work by reducing the absorption of glucose via the kidneys so that excess glucose is excreted through urination.
Read More »Empagliflozin Use in People with Type 2 and History of Coronary Artery Bypass Graft Surgery (CABG)
Research still limited in regard to SGLT2 inhibitor use and its ability to reduce CVD risk in patients after revascularization
Read More »Endogenous Glucose Production After Treatment with Canagliflozin and Liraglutide
Pancreatic hormones, glucagon and insulin said partially responsible for unintended increase in glucose.
Read More »When and When Not to Use An SGLT-2
After reviewing evidence, a tool to evaluate benefit and risk has been developed for the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors.
Read More »Empagliflozin’s Effect on Liver Fat
An SGLT-2 inhibitor reduces liver fat and ALT levels in people who have type 2 diabetes.
Read More »SGLT-2 Inhibitors: What You and Your Patient Should Know to Prevent DKA
Teach patients what DKA is and how to prevent it. Include in your teaching that glucose can be normal or only slightly elevated and it can still happen. Teach that having an illness and/or dehydration increases this risk.
Read More »Less Insulin for Patients With Type 2 That Add On An SGLT2 Inhibitor
Adding an SGLT2 inhibitor to insulin therapy for patients with type 2 diabetes who'd required large doses of insulin helped them reduce their insulin dose.
Read More »